Synergistic effect of two human-like monoclonal antibodies confers protection against orthopoxvirus infection

• Published in: Nature communications 2024-04, Vol.15 (1), p.3265-10, Article 3265
• Main Authors: Tamir, Hadas, Noy-Porat, Tal, Melamed, Sharon, Cherry-Mimran, Lilach, Barlev-Gross, Moria, Alcalay, Ron, Yahalom-Ronen, Yfat, Achdout, Hagit, Politi, Boaz, Erez, Noam, Weiss, Shay, Rosenfeld, Ronit, Epstein, Eyal, Mazor, Ohad, Makdasi, Efi, Paran, Nir, Israely, Tomer
• Format: Article
• Language: English
• Subjects: 59/5; 631/1647/334/1874/345; 631/326/22/1295; 631/326/596; 631/326/596/1746; 64/60; Animals; Antibodies, Monoclonal; Antibodies, Viral; Clearances; Female; Females; Humanities and Social Sciences; Humans; Immunization; Medical imaging; Mice; Monoclonal antibodies; Mpox; Mpox (monkeypox); multidisciplinary; Neutralization; Orthopoxvirus; Poxviridae Infections - prevention & control; Science; Science (multidisciplinary); Smallpox; Synergistic effect; Vaccination; Vaccines; Vaccinia; Vaccinia virus; Viruses
• ISSN: 2041-1723; 2041-1723
• DOI: 10.1038/s41467-024-47328-y

The eradication of smallpox was officially declared by the WHO in 1980, leading to discontinuation of the vaccination campaign against the virus. Consequently, immunity against smallpox and related orthopoxviruses like Monkeypox virus gradually declines, highlighting the need for efficient countermeasures not only for the prevention, but also for the treatment of already exposed individuals. We have recently developed human-like monoclonal antibodies (mAbs) from vaccinia virus-immunized non-human primates. Two mAbs, MV33 and EV42, targeting the two infectious forms of the virus, were selected for in vivo evaluation, based on their in vitro neutralization potency. A single dose of either MV33 or EV42 administered three days post-infection (dpi) to BALB/c female mice provides full protection against lethal ectromelia virus challenge. Importantly, a combination of both mAbs confers full protection even when provided five dpi. Whole-body bioimaging and viral load analysis reveal that combination of the two mAbs allows for faster and more efficient clearance of the virus from target organs compared to either MV33 or EV42 separately. The combined mAbs treatment further confers post-exposure protection against the currently circulating Monkeypox virus in Cast/EiJ female mice, highlighting their therapeutic potential against other orthopoxviruses. In this study, the authors show that a single dose of a combination of two human-like monoclonal antibodies protect mice in therapeutic treatment against challenges with ectromelia virus and monkeypox virus. Combination treatment provided more effective viral clearance than single antibody treatment.